FDA Warns Against Unapproved Compounded GLP-1 Medications

The FDA has issued a warning regarding compounded GLP-1 drugs, such as semaglutide and tirzepatide, due to potential safety risks. The agency highlighted several red flags for consumers, including lack of prescription, unknown manufacturers, and improper shipping conditions. These issues can lead to impurities, incorrect dosing, or sterility problems, posing serious health concerns.